Clinical Trials Logo

Placenta Accreta clinical trials

View clinical trials related to Placenta Accreta.

Filter by:

NCT ID: NCT05471102 Recruiting - Placenta Accreta Clinical Trials

Ligation of Anterior Internal Iliac Artery With Conservative Management of Partial or Focal Placenta Accreta Spectrum

Start date: July 3, 2022
Phase: N/A
Study type: Interventional

The patients will be divided into 2 groups: Group (A) - Study group: Cases managed by lower segment resection with ligation of the anterior division of the internal iliac artery Group (B) - Control group: Cases managed by lower segment resection without ligation of the anterior division of the internal iliac artery The following operative details will be recorded: - Estimation of total blood loss - Pre and 24-h post-operative hemoglobin (g/dl). - The need for blood transfusion and its amount intra or postoperative will be recorded - Operative time and postoperative hospital stay will be recorded. - Close post-operative monitoring of the patients' vital signs, drain output, and urine output - Presence or absence of intraoperative complications; bladder, ureteric, bowel, or vascular injuries will be recorded. - Monitoring for postoperative morbidities

NCT ID: NCT05419804 Completed - Placenta Accreta Clinical Trials

Placenta Accreta; Total Lower Uterine Segmentectomy With Cervico-corporeal Anastomosis

Start date: June 1, 2022
Phase:
Study type: Observational

To study feasibility and safety of Total lower uterine segmentectomy with cervico-corporeal anastomosis in conservative management of placenta accreta

NCT ID: NCT05376410 Recruiting - Clinical trials for Placenta Accreta, Third Trimester

Relationship Between Maternal Soluble Trigger Receptor Expressed on Myeloid Cells-1 (sTREM-1) and Placenta Accreta Spectrum

Start date: November 14, 2021
Phase:
Study type: Observational

We planed to evaluate soluble the triggering receptors expressed on myeloid cell-1 (s TREM-1) levels in serum of pregnant women diagnosed with placenta accreta spectrum and compare it with healthy pregnant women's s TREM-1 serum levels.

NCT ID: NCT05314595 Not yet recruiting - Placenta Accreta Clinical Trials

Bilateral Uterine Artery Ligation in PPC Technique for Management of PAS

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Aim of the study Primary outcomes: 1. The effect of bilateral uterine artery ligation in reducing intraoperative bleeding in women underwent PPC as a conservative surgical technique. 2. Decrease surgical time. Secondary outcomes: 1. Associated maternal morbidity and mortality. 2. Amount of blood transfusion 3. Difference in hematocrit value before and after delivery

NCT ID: NCT05232981 Recruiting - Placenta Accreta Clinical Trials

Conservative Treatment of PAS With or Without IIL

PASIIL
Start date: May 1, 2022
Phase: N/A
Study type: Interventional

In the current study, the investigators aimed to compare the benefits of internal iliac ligation in placenta accreta spectrum

NCT ID: NCT05205304 Recruiting - Placenta Accreta Clinical Trials

The Role of Transdermal CO2 in MDA Level in Patient Underwent Abdominal Aortic Temporary Cross Clamp

Start date: March 1, 2022
Phase: Phase 4
Study type: Interventional

The Role of Transdermal Carbon Dioxide in Malondialdehyde Level as Predictor of Ischemia Reperfusion Injury in Patients Underwent Abdominal Aortic Temporary Cross Clamp

NCT ID: NCT05191316 Not yet recruiting - Clinical trials for Placenta Accreta, Third Trimester

the Efficacy and Safety of the 3-steps Conservative Approach in the Management of Placenta Accreta Spectrum (a Novel Technique)

Start date: February 15, 2022
Phase:
Study type: Observational

Placenta accrete spectrum (PAS) is an heterogeneous condition associated with a high maternal morbidity and mortality rate, presenting unique challenges in its diagnosis and management (Morlandoi et al., 2020). PAS describes a clinical situation where the placenta does not detach spontaneously after delivery and cannot be forcibly removed without causing massive and potentially life-threatening bleeding (Jauniaux et al., 2018), in this study we study a novel 3-step technique for surgical conservative management of PAS, in terms of efficacy and safety.

NCT ID: NCT05139498 Recruiting - Placenta Accreta Clinical Trials

Conservative Management for PAS Pilot

Start date: May 26, 2022
Phase: N/A
Study type: Interventional

Conservative in situ management is a promising alternative treatment to hysterectomy for patients with placenta accreta spectrum and may be safer and preferable for some patients. This study will assess feasibility of a future randomized clinical trial comparing these treatments and provide novel data to inform shared decision-making and cost-effective care for patients with this deadly pregnancy disorder.

NCT ID: NCT05104177 Not yet recruiting - Placenta Accreta Clinical Trials

Effectivness of Conservative Techniques in Management of PAS

Start date: November 2021
Phase:
Study type: Observational [Patient Registry]

To evaluate the effectiveness of conservative techniques for placenta accreta spectrum to reduce maternal mortality and morbidity

NCT ID: NCT05070689 Recruiting - Placenta Accreta Clinical Trials

Placenta Accreta Spectrum Disorders: A. Chohan Continuous Squeezing Suture (ACCSS)

ACCSS
Start date: November 15, 2021
Phase: N/A
Study type: Interventional

Placenta Accreta Spectrum (PAS) disorders are rising in incidence due to increased rate of repeat caesarean sections. Peripartum hysterectomy remains the only definitive treatment of massive postpartum haemorrhage related to this condition. Researchers have described conservative treatments in the form of pelvic devascularization under radiological control, myometrial resection with placenta in situ, and various suturing techniques some involving inversion of cervix. Variable success rates are described, but search continues for a simple, safe and effective treatment. The objective of this study is to assess the simplicity, safety and efficacy of A. Chohan Continuous Squeezing Suture (ACCSS) in the management of PAS.